Scopus BioPharma ^{Priced, Nasdaq: SCPS}

We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we are capitalizing on groundbreaking scientific and medical discoveries at some of the world’s foremost research and academic institutions. Our lead development program is a novel, first-in-class, targeted immuno-oncology gene therapy for the treatment of multiple cancers. We have partnered with City of Hope, or COH, for CpG-STAT3siRNA, a STAT3 inhibitor gene therapy. In pre-clinical testing at City of Hope, our STAT3 inhibitor has successfully reduced growth and metastasis of various pre-clinical tumor models, including melanoma, and colon and bladder cancers, as well as leukemia and lymphoma. An investigational new drug application, or IND, for our STAT3 inhibitor for B-cell lymphoma is currently anticipated to be filed with the United States Food and Drug Administration, or FDA, in Q4 2020. We currently anticipate that a first-in-human Phase 1 clinical trial for B-cell lymphoma will commence in Q1 2021.